Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg, the generic version of Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg of Allergan Sales, LLC.
According to IMS Health sales data for the 12 month period ending February 2017, the Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg market achieved annual sales of approximately $154.4 million.
Glenmark’s current portfolio consists of 113 products authorized for distribution in the US marketplace and 65 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1530.00 |
Dr. Reddys Lab | 5802.00 |
Cipla | 1399.35 |
Zydus Lifesciences | 1051.90 |
Lupin | 1653.75 |
View more.. |